相关实验视频

Updated: Jul 6, 2025

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
08:53

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

391

比瓦利鲁丁-水凝涂层的聚乙烯化物在体外膜氧化对抗凝固的抗凝固

Wenqing Gao1,2,3,4, Hechen Shen1,2,4,5, Yun Chang1,2,3,4

  • 1Department of Cardiac Center, Tianjin Third Central Hospital, Tianjin, China.

Frontiers in cardiovascular medicine
|January 1, 2024
PubMed
概括

一种新的凝甲基酸水凝涂层与Bivalirudin (BV) 为医疗器械提供了卓越的抗凝作用. 与传统的肝素相比,这种BV-Coating GelMA水凝降低了出血风险,提高了体外膜氧化 (ECMO) 的安全性.

关键词:
比瓦利鲁丁 (Bivalirudin) 是一种可以这是一种抗凝血药物.生物相容性 生物相容性身体外膜氧化氧化水凝涂层是用水凝涂层进行的.聚乙烯化物 聚乙烯化物

更多相关视频

An In Vitro Hemodynamic Loop Model to Investigate the Hemocytocompatibility and Host Cell Activation of Vascular Medical Devices08:44

An In Vitro Hemodynamic Loop Model to Investigate the Hemocytocompatibility and Host Cell Activation of Vascular Medical Devices

Published on: August 21, 2020

7.2K
In Vitro Thrombosis Test for Ventricular Assist Devices09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

603

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
702
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.7K